MedTrace Logo

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

NCT06515730 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2025-07-01

No results posted yet for this study

Summary

The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.

Conditions

  • Left Ventricular Thrombus
  • Acute Myocardial Infarction

Interventions

DRUG

Apixaban

5 mg tablet twice a daily with dose reduction according to label

DRUG

Warfarin

2.5 mg tablet once daily, with individual dosing according to coagulation tests

Sponsors & Collaborators

  • Karolinska Trial Alliance

    collaborator INDUSTRY

  • Swedish Heart Lung Foundation

    collaborator OTHER

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Stockholm County Council ALF/PPG

    collaborator UNKNOWN

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Moa Simonsson, MD, PhD · Department of Medicine Solna, Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-08
Primary Completion
2028-04-08
Completion
2028-07-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06515730 on ClinicalTrials.gov